REFERENCES
- Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
- Panel on Antiretroviral Guidelines for Adults and Ado-lescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1–139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 5,2009.
- European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. 2008. Available at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf.
- Cuzin L, Allavena C, Morlat P, Dellamonica P. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: Is there a best choice for antiretroviral-naive HIV-1 infected patients? AIDS Rev. 2008;10:205–211.
- Boyd M. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS. 2009;4(3)194–199.
- Cui Y, Blumenthal RS, Flaws JA. Non-high-density lipo-protein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001161: 1413–1419.
- D:A:D Study Group. Class of antiretoviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356: 1723–1735.
- Dube MP, Stein JH, Aberg JA, et al, for the Adult AIDS Clin-ical Trials Group Cardiovascular Subcommittee. Guide-lines for the evaluation and management of dyslipidemia in Human Immunodeficiency Virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Soci-ety of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627.
- Ruane PJ, Luber AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administra-tion of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2007;51:560–565.
- Hicks C, DeJesus E, Sloan L, et al. Once daily fosampre-navir (FPV) with a reduced dose of ritonavir (RTV), given with abacavir (ABC)/lamivudine (3TC) combination tablet: a planned Week 24 interim analysis of the REDUCE Study. In: Program and abstracts of the Ninth International Con-gress on Drug Therapy in HIV Infection; November 12–16, 2006; Glasgow, UK. Abstract P2.
- French ANRS AC11 Group. 2006. HIV-1 genotypic drug resistance interpretation's algorithms. Table of rules 2006. Available at: http://www.hivfrenchresistance.org/2006/tab2.
- Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. 2004. Avail-able at: http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/DAIDSAEGradingTable.pdf.
- Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008;16(5)1 38–145.
- Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics. 1988;44:579–585.
- Hughes S, Cuffe R, Lieftucht A, Nichols WG. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial. Pharmaceut Statist. 2008. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/pst.323.
- NCEP (National Cholesterol Education Program). Detec-tion, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel 111). Available at: http://www.nhIbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed December 22,2008.
- Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2009;22(12):1389–1397.
- Molina J, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):645–655.
- Austin MA, Hokanson JE, Edwards KL. Hypertriglyc-eridaemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B.
- Badiou S, Thiebaut R, Aurillac-Lavignolle V, et al. Associa-tion of non-HDL cholesterol with subclinical atherosclero-sis in HIV-positive patients. J Infect. 2008;57:47–54.
- Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collab-orative Ritonavir Study Group. N Engl J Med. 1995;333:–1528–1533.